ERCP: Clinical Trials

4 trials for ERCP, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 terminated. 4 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 34Completed 3, Terminated 1
Phase 21Terminated 1

Follow ERCP: new trials by email Literature Review of ERCP trials Research Report on ERCP

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Prophylaxis Against Post-Endoscopic Retrograde Cholangio-Pancreatography Pancreatitis.
Rectal Indometacin - Pancreatitis, ERCP
Phase 3CompletedHospital General de Chihuahua - Dr. Salvador Zubirán Anchondo602024-03-042026-05-20
PPI for Prevention of Post-sphincterotomy Bleeding
Esomeprazole, Standard care - Bleeding, ERCP
Phase 3CompletedThe University of Hong Kong1852013-04-012016-07-18
Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP)
Drotaverine hydrochloride, Hyoscine-N-butylbromide - ERCP, Pancreatic Diseases
Phase 3CompletedChanghai Hospital6502008-08-012010-09-08
Efficacy Study of Glyceryl-Trinitrate Patch and Parecoxib (Valdecoxib) for the Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography (ERCP)
Glyceryl - trinitrate, Valdecoxib - ERCP, Pancreatitis
Phase 2 / Phase 3TerminatedAll India Institute of Medical Sciences3712003-10-012009-01-29

Narrower conditions

Pancreatitis (2)  ·  Bile Duct Diseases (1)  ·  Hemorrhage (1)  ·  Pancreatic Diseases (1)

Broader conditions

Digestive System Diseases (3)  ·  Pancreatic Diseases (2)  ·  Biliary Tract Diseases (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

Butylscopolammonium Bromide (1)  ·  Cholangiopancreatography, Endoscopic Retrograde (1)  ·  Esomeprazole (1)  ·  Nitroglycerin (1)  ·  Standard of Care (1)  ·  drotaverin (1)  ·  valdecoxib (1)

Sponsors

All India Institute of Medical Sciences (1)  ·  Changhai Hospital (1)  ·  Hospital General de Chihuahua - Dr. Salvador Zubirán Anchondo (1)  ·  The University of Hong Kong (1)

Countries

China (2)  ·  India (1)  ·  Mexico (1)

Top investigators

Pramod K Garg, M.D., D.M. (1)  ·  Vikram Bhatia, M.D., D.M. (1)  ·  Wai K Leung, MD (1)  ·  Zhaoshen Li, MD (1)